OncLive TV

Dr. Brown on Lessons Learned From RESONATE-2 Trial for CLL

September 6th 2016

Jennifer Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the lessons oncologists have learned from the RESONATE-2 trial, which showed a benefit with ibrutinib (Imbruvica) over chlorambucil in patients with chronic lymphocytic leukemia (CLL).

Dr. Levine on Evolving Treatment Options for Patients With mCRPC

September 5th 2016

Richard M. Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer.

Dr. Sunil Verma on Treatment for Early HER2+ Breast Cancer

September 2nd 2016

Dr. Leslie M. Randall on Early BRCA Testing in Ovarian Cancer

September 2nd 2016

Dr. Joshua M. Bauml on the Impact of Pembrolizumab in Head and Neck Cancer

September 2nd 2016

Dr. Johnstone on Immediate Salvage Therapy for Prostate Cancer

September 2nd 2016

Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

September 2nd 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCC

September 1st 2016

Michael L. Blute, MD, chair of Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Sharma on Tolerability of SIRT in Patients With CRC

September 1st 2016

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) when added to chemotherapy for patients with colorectal cancer (CRC) that has metastasized to the liver.

Dr. Areej El-Jawahri on the Impact of Palliative Care

September 1st 2016

Dr. Barbara J. Gitlitz on Why PD-L1 is Not a Good Biomarker for Immunotherapy in Lung Cancer

September 1st 2016

Dr. Kathy S. Albain on Breast Cancer Risk After 5 Years of Tamoxifen

September 1st 2016

Dr. White on Relationship Between Multigene Assays and RT in Breast Cancer

September 1st 2016

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the relationship between multigene assays and radiation therapy in patients with breast cancer.

Dr. Pennell on Importance of EGFR Testing in NSCLC

August 31st 2016

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

Dr. Leora Horn on Toxicities With Immunotherapy in Lung Cancer

August 31st 2016

Dr. Anderson on Future Treatment Landscape of Multiple Myeloma

August 30th 2016

Kenneth C. Anderson, MD, a 2014 Giant of Cancer Care in Myeloma, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, institute physician, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how currently available agents will continue to impact the field of multiple myeloma.

Dr. O'Connor on Ongoing Breast Cancer Research

August 30th 2016

Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.

Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

August 30th 2016

Dr. Julio Pow-Sang on Options for Low-and Intermediate-Risk Prostate Cancer

August 30th 2016

Dr. Chandarlapaty on Role of the PI3K Pathway in Breast Cancer

August 29th 2016

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3k pathway in patients with metastatic breast cancer.